Effect of Oxygen Administration in the Non-dependent Lung on Postoperative Complications After Lung Surgery
Condition(s) studied
Investigational drug(s) / intervention(s)
Medicinal gas - oxygen (Nippon Gases 200 bar): Medicinal gas, compressed. Oxygen 99.5% v/v
CPAP: Continuous positive pressure
Oxygen therapy according to standard clinical practice: Ambient air connection
Study summary
The purpose of this study is to analyze the effectiveness of apneic oxygenation and CPAP applied to the non-dependent lung during pulmonary resection surgery in reducing inflammatory response, ischemia-reperfusion injury, and postoperative complications. We will conduct a randomized, controlled, and blinded study in 177 patients with three arms:
* Control Group: Oxygen therapy according to standard clinical practice
* Apneic oxygenation group: A probe will be introduced through the lumen of the double-lumen tube (DLT) to administer a continuous source of oxygen without any mechanism that generates airway pressure.
* CPAP Group: Continuous positive airway pressure with 3-5 L/min oxygen flow and 2 cm H2O pressure delivered via a Mapleson system.
Inflammatory mediators in blood and in both lungs will be measured intraoperatively and 24 hours after surgery. Patients will be followed from hospital admission until discharge and again 30 days after surgery to evaluate the postoperative course, particularly the occurrence of complications according to the revised Clavien-Dindo classification for thoracic surgery, as well as other relevant clinical outcomes.
Eligibility
Primary outcome measure(s)
- Postoperative complications — Up to 30 days after intervention
To compare the proportion of patients in each grade of the revised Clavien-Dindo classification for thoracic surgery across the three study groups
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hospital General Universitario Gregorio Marañón | Madrid | Spain | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07461779 on ClinicalTrials.gov ↗ ← All trials in Spain